The National Institute of Standards and Technology Genome Editing Consortium addresses the measurements and standards needed to increase confidence and lower the risk of utilizing genome editing technologies in research and commercial products. This consortium is currently active. Please see below for more detailed information on current activities.
Access to a neutral forum for addressing pre-competitive needs
Participation in the development of experimental benchmarks, guidelines and terminology
Access to tools developed by the consortium ahead of public release
Institutional representation on consortium steering committee
BECOME A MEMBER
Annual fee of $20,000 or in-kind support of equivalent value
Participants will sign a Cooperative Research and Development Agreement
Targeted genome editing, a method used to alter the DNA of living cells at desired locations, is poised to revolutionize science and medicine. To fight diseases, novel genome edited therapeutics, including those for use in regenerative medicine and infectious diseases, are being developed. Many commercial applications including agriculture and chemical production, are also leveraging this technology. Whether genome editing will be used in healthcare, agriculture or basic research, robust quantitative measurements are needed to enable high confidence characterization of DNA alterations. NIST has brought together experts across the genome editing field including stakeholders in industry, academia and government to assess their measurement needs. These discussions have identified common pre-competitive measurements and standards needed to establish greater confidence in the characterization of genome editing outputs. The NIST-led Genome Editing Consortium has been established to address these needs.
Evaluate genome editing assay pipelines
Develop benchmark materials
Generate benchmark data
Develop suggested minimal information reporting for public studies
Generate a common lexicon for genome editing studies
Three working groups with the following responsibilities:
Design, generate, and evaluate cell and DNA based control materials and test via interlab analysis. Control materials will be used as benchmarks for assessing next-generation sequencing (NGS) pipelines and other platforms intended to identify induced genome editing events.
Design and conduct controlled evaluations of existing assays for quantifying on- and off-target genome editing, with a robust and optimal experimental design aimed at assessing the sources of variability, repeatability, and reproducibility within an assay